Pentixapharm Holding AG has announced the publication of new Phase 2 clinical data supporting the use of [68Ga]Ga-Pentixafor as a non-invasive imaging tool for primary aldosteronism (PA), a major endocrine cause of hypertension. Published in the Journal of Nuclear Medicine on February 5, 2026, the findings suggest that this PET/CT imaging technique offers high specificity and moderate sensitivity for identifying unilateral aldosterone-producing adenomas.
The study highlights that [68Ga]Ga-Pentixafor PET/CT was well tolerated among participants. Researchers found that it demonstrated a superior ability to identify specific types of adrenal tumors compared to traditional methods such as adrenal vein sampling (AVS) and surgical outcomes. This data underscores the importance of molecular imaging in clinical settings, potentially guiding treatment decisions for patients suffering from hypertension linked to primary aldosteronism.
Significance of the Findings
The relevance of these results extends beyond mere statistical significance; they strengthen the clinical foundation for advancing into Phase 3 trials. As the prevalence of hypertension continues to rise globally, effective diagnostic tools are crucial for managing the condition. The ability of [68Ga]Ga-Pentixafor to identify aldosterone-producing adenomas non-invasively could revolutionize the approach to diagnosing and treating patients with PA.
According to the research findings, the specificity of the imaging technique was notably high, meaning it accurately identified true positive cases of unilateral adenomas. This contrasts with the moderate sensitivity, which indicates that while it can miss some cases, the overall benefits of non-invasive testing offer a promising alternative to more invasive procedures.
Future Directions
The promising results from this Phase 2 study pave the way for further exploration into PENTIXAFOR‘s clinical applications. As Pentixapharm prepares for Phase 3 development, the focus will shift to larger patient populations to validate these findings. The company aims to enhance the diagnostic landscape for hypertension, particularly among those with underlying conditions like primary aldosteronism.
In summary, Pentixapharm’s recent study presents a significant advancement in the field of molecular imaging for hypertension-related conditions. As the development progresses, health professionals may soon have access to a powerful new tool designed to improve patient outcomes in the management of primary aldosteronism.
